Evidence map›Paper›PMID 42349425›Full record

ArticleStem cell reports2026

A highly efficient method to differentiate CGRP-expressing peptidergic nociceptors from human induced pluripotent stem cells.

Galbha Duggal, Xinyu Li, Philippa Pettingill, Tatjana Lalic, Shailesh Kumar Gupta, Christine Flodgaard Høgsbro, Viola Volpato, Caleb Webber, Rory Bowden, Despoina Charou and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Stem cell reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Galbha DuggalNuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK; Oxford StemTech, The Oxford Science Park, Oxford, UK. Electronic address: galbha.duggal@oxfordstemtech.com.
Xinyu LiNuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK.
Philippa PettingillNuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK.
Tatjana LalicNuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK.
Shailesh Kumar GuptaGlobal Portfolio & Project Management, Oncology R&D, Cambridge, UK.
Christine Flodgaard HøgsbroDepartment of Neurology, Faculty of Health and Medical Sciences, Danish Headache Center, Glostrup Hospital, University of Copenhagen, Glostrup, Denmark.
Viola VolpatoUK Dementia Research Institute, Department of Psychological Medicine and Clinical Neuroscience, Cardiff University, Cardiff, UK.
Caleb WebberUK Dementia Research Institute, Department of Psychological Medicine and Clinical Neuroscience, Cardiff University, Cardiff, UK.
Rory BowdenWellcome Trust Centre for Human Genetics, University of Oxford, Oxford, UK.
Despoina CharouNuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK.
Kanisa ArunasalamNuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK.
Marcello MarescaDiscovery Biology, Discovery Sciences IMED Biotech Unit, AstraZeneca, Gothenburg, Sweden.
Ryan HicksBioanalytical and Biomarker Labs, Thermofisher Scientific, Gothenburg, Sweden.
Satyan ChintawarNuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK; Oxford StemTech, The Oxford Science Park, Oxford, UK.
M Zameel CaderNuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK; Oxford StemTech, The Oxford Science Park, Oxford, UK. Electronic address: zameel.cader@ndcn.ox.ac.uk.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Pain disorders such as neuropathic pain and headache remain areas of considerable unmet need and considered high risk by pharma. Human-induced pluripotent stem cells (iPSC)-derived sensory neurons have already been used to accelerate translational research but the current differentiation protocols produce non-peptidergic nociceptors. We demonstrate for the first time the robust differentiation of hiPSC into peptidergic nociceptor lineage with high yield. These nociceptors express CGRP and TRPV1 and show functional maturity including the expression of TTX-resistant currents and responding to TRPV1 and TRPA1 agonists. Importantly, they were able to release CGRP basally and upon stimulation by inflammatory soup, which was inhibited upon the application of the 5-HT

Indexed as

Calcitonin Gene-Related PeptideCell DifferentiationInduced Pluripotent Stem CellsNociceptorsHumansSumatriptanTRPV Cation ChannelsCalcitonin Gene-Related PeptideSumatriptanTRPV Cation ChannelsCGRPhumaninflammationiPSCmigrainenociceptorpainpeptidergicsensory neuronstrigeminal

Identifiers

PMID42349425
PMCPMC13385448

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.